1121 related articles for article (PubMed ID: 23795575)
21. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin.
Yoon YK; Kim JY; Park DW; Sohn JW; Kim MJ
J Antimicrob Chemother; 2010 May; 65(5):1015-8. PubMed ID: 20200036
[TBL] [Abstract][Full Text] [Related]
22. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
[TBL] [Abstract][Full Text] [Related]
23. Outcomes and costs associated with a history of vancomycin exposure in patients with MRSA-related complicated bacteremia and infective endocarditis.
Brown J; Brown KA; Forrest A
Clin Ther; 2011 Oct; 33(10):1475-82. PubMed ID: 21925733
[TBL] [Abstract][Full Text] [Related]
24. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
[TBL] [Abstract][Full Text] [Related]
25. Impact of initial vancomycin pharmacokinetic/pharmacodynamic parameters on the clinical and microbiological outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children.
Yoo R; So H; Seo E; Kim M; Lee J
PLoS One; 2021; 16(4):e0247714. PubMed ID: 33793589
[TBL] [Abstract][Full Text] [Related]
26. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?
Lodise TP; Drusano GL; Zasowski E; Dihmess A; Lazariu V; Cosler L; McNutt LA
Clin Infect Dis; 2014 Sep; 59(5):666-75. PubMed ID: 24867791
[TBL] [Abstract][Full Text] [Related]
27. Methicillin-resistant Staphylococcus aureus (MRSA) staphylococcal cassette chromosome mec genotype effects outcomes of patients with healthcare-associated MRSA bacteremia independently of vancomycin minimum inhibitory concentration.
Chen SY; Liao CH; Wang JL; Chiang WC; Lai MS; Chie WC; Chen WJ; Chang SC; Hsueh PR
Clin Infect Dis; 2012 Nov; 55(10):1329-37. PubMed ID: 22911641
[TBL] [Abstract][Full Text] [Related]
28. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 microg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis.
Maclayton DO; Suda KJ; Coval KA; York CB; Garey KW
Clin Ther; 2006 Aug; 28(8):1208-1216. PubMed ID: 16982298
[TBL] [Abstract][Full Text] [Related]
29. Relevance of vancomycin-intermediate susceptibility and heteroresistance in methicillin-resistant Staphylococcus aureus bacteraemia.
Khatib R; Jose J; Musta A; Sharma M; Fakih MG; Johnson LB; Riederer K; Shemes S
J Antimicrob Chemother; 2011 Jul; 66(7):1594-9. PubMed ID: 21525024
[TBL] [Abstract][Full Text] [Related]
30. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.
Moise PA; Culshaw DL; Wong-Beringer A; Bensman J; Lamp KC; Smith WJ; Bauer K; Goff DA; Adamson R; Leuthner K; Virata MD; McKinnell JA; Chaudhry SB; Eskandarian R; Lodise T; Reyes K; Zervos MJ
Clin Ther; 2016 Jan; 38(1):16-30. PubMed ID: 26585355
[TBL] [Abstract][Full Text] [Related]
31. Predicting high vancomycin minimum inhibitory concentration isolate infection among patients with community-onset methicillin-resistant Staphylococcus aureus bacteraemia.
Chen SY; Hsueh PR; Chiang WC; Huang EP; Lin CF; Chang CH; Chen SC; Chen WJ; Chang SC; Lai MS; Chie WC
J Infect; 2014 Sep; 69(3):259-65. PubMed ID: 24797078
[TBL] [Abstract][Full Text] [Related]
32. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs.
Arun A; Swamy S; Jacob K; Sharma R; Kohlhoff SA; Hammerschlag MR
Minerva Pediatr; 2018 Jun; 70(3):207-211. PubMed ID: 28006894
[TBL] [Abstract][Full Text] [Related]
34. Vancomycin AUC24 /MIC Ratio in Patients with Methicillin-Resistant Staphylococcus aureus Pneumonia.
Ji M; Kim HK; Kim SK; Lee W; Sung H; Chun S; Kim MN; Min WK
J Clin Lab Anal; 2016 Sep; 30(5):485-9. PubMed ID: 26499918
[TBL] [Abstract][Full Text] [Related]
35. Vancomycin Trough Concentration as a Predictor of Clinical Outcomes in Patients with Staphylococcus aureus Bacteremia: A Meta-analysis of Observational Studies.
Prybylski JP
Pharmacotherapy; 2015 Oct; 35(10):889-98. PubMed ID: 26497475
[TBL] [Abstract][Full Text] [Related]
36. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations.
Holmes NE; Turnidge JD; Munckhof WJ; Robinson JO; Korman TM; O'Sullivan MV; Anderson TL; Roberts SA; Gao W; Christiansen KJ; Coombs GW; Johnson PD; Howden BP
J Infect Dis; 2011 Aug; 204(3):340-7. PubMed ID: 21742831
[TBL] [Abstract][Full Text] [Related]
37. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
Clemens EC; Chan JD; Lynch JB; Dellit TH
Diagn Microbiol Infect Dis; 2011 Dec; 71(4):408-14. PubMed ID: 21924852
[TBL] [Abstract][Full Text] [Related]
38. Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.
Brown J; Brown K; Forrest A
Antimicrob Agents Chemother; 2012 Feb; 56(2):634-8. PubMed ID: 22123681
[TBL] [Abstract][Full Text] [Related]
39. Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections.
Claeys KC; Zasowski EJ; Casapao AM; Lagnf AM; Nagel JL; Nguyen CT; Hallesy JA; Compton MT; Kaye KS; Levine DP; Davis SL; Rybak MJ
Antimicrob Agents Chemother; 2016 Oct; 60(10):5841-8. PubMed ID: 27431221
[TBL] [Abstract][Full Text] [Related]
40. Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study.
Murray KP; Zhao JJ; Davis SL; Kullar R; Kaye KS; Lephart P; Rybak MJ
Clin Infect Dis; 2013 Jun; 56(11):1562-9. PubMed ID: 23449272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
